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Abstract: As the most common chronic degenerative joint disease, osteoarthritis (OA) is the leading
cause of pain and physical disability, affecting millions of people worldwide. Mainly characterized
by articular cartilage degradation, osteophyte formation, subchondral bone remodeling, and synovial
inflammation, OA is a heterogeneous disease that impacts all component tissues of the articular joint
organ. Pathological changes, and thus symptoms, vary from person to person, underscoring the critical
need of personalized therapies. However, there has only been limited progress towards the prevention
and treatment of OA, and there are no approved effective disease-modifying osteoarthritis drugs
(DMOADs). Conventional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs)
and physical therapy, are still the major remedies to manage the symptoms until the need for total
joint replacement. In this review, we provide an update of the known OA risk factors and relevant
mechanisms of action. In addition, given that the lack of biologically relevant models to recapitulate
human OA pathogenesis represents one of the major roadblocks in developing DMOADs, we discuss
current in vivo and in vitro experimental OA models, with special emphasis on recent development
and application potential of human cell-derived microphysiological tissue chip platforms.
Keywords: osteoarthritis; pathogenesis; experimental model; disease modifying osteoarthritis drugs;
microphysiological systems
1. Introduction
Existing since ancient times and officially named and defined in the 19th century [1], osteoarthritis
(OA) has been the most common degenerative joint disease. According to data collected by US Centers
for Disease Control and Prevention, OA affects 52.5 million people in the United States in 2012 and the
number is expected to go up to 78 million (26%) by 2040 [2]. In the 2010 Global Burden of Disease
report, OA was the 11th highest global disability contributor out of 291 health conditions studied [3],
affecting both physical and mental health and with substantial healthcare costs [4]. Data from the
National Institutes of Health Osteoarthritis Initiative (OAI) study demonstrated that people with
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multi-site, hip, or knee OA have greater odds of developing depression-related symptoms as compared
to people without OA [5]. Greater suicidal ideation odds and memory loss, partially mediated by sleep
and mood impairments caused by joint symptoms, are found in OA patients [6,7]. Commonly affected
joints are large weight-bearing joints, such as the knee and hip [8], that are characterized by synovial
distension and inflammation, thin and rough articular cartilage, and reactive bone hyperplasia at the
joint edge and beneath the cartilage [9]. Radiographically, OA presents with joint space narrowing,
osteophytosis, subchondral sclerosis, cyst formation, and abnormalities of bone contour [10,11]. These
changes cause pain, stiffness, tenderness, and loss of mobility that often arise near the end of disease
progression, greatly impacting patients’ life quality and even leading to mortality [12]. Current OA
prevalence is ~15% and is predicted to reach 35% by 2030, making it the single greatest cause of
disability globally. Although it remains unclear why the prevalence of OA is rising, the most likely
factor is the increase of obese and aged populations [13].
OA is characterized as a failure of the joint organ that affects all the tissues in and around
the joint, these affects include degradation of the articular cartilage; thickening of the subchondral
bone; osteophyte formation; variable degrees of synovial inflammation; degeneration of ligaments;
hypertrophy of the joint capsule; and changes in periarticular muscles, nerves, bursa, and local fat
pads [14]. Among these, cartilage degradation is considered to be the central feature [15]. This is
because articular cartilages are anatomically at the frontline to respond to the local biomechanical
environmental, specifically absorbing and distributing mechanical loads applied to the articular joint
and providing a low friction system to enable mobility. Highly regulated anabolic and catabolic
mechanisms maintain and adapt cartilage to disruptive factors [16]. In OA, dysregulation caused by
the presence of various biofactors leads to the loss of cartilage homeostasis, resulting in degradation of
the collagen- and proteoglycan-rich extracellular matrix (ECM), fibrillation and erosion of the articular
surface, cell death, matrix calcification, and vascular invasion [17].
Despite the disease being known for centuries, the exact pathogenic mechanisms of OA remain
unclear. Initially, OA was considered an unavoidable age-related disease caused by biomechanical
factors, i.e., “wear-and-tear”, and an imbalance in the homeostatic biochemical mechanisms of cartilage,
distinct from immunologically-mediated rheumatoid arthritis [18]. However, detailed examination
revealed patient-specific variability in the clinical presentation and disease progression [19]. Most cases
of OA have a clear predisposing condition, such as genetics, trauma, aging, or obesity, leading to the idea
that OA describes a common endpoint with different etiologies. In any case, it is now widely accepted
that OA is a dynamic and complex process, involving inflammatory, mechanical, and metabolic factors
that result in the inability of the articular surface to serve its function of absorbing and distributing the
mechanical load through the joint that ultimately leads to joint destruction [11]. Furthermore, it is now
recognized that the disease is not restricted to the cartilage or subchondral bone; rather, it results from
interplay among tissues of the osteochondral complex, including adipose and synovial tissue, as well
as the ligaments, tendon, and muscles that surround the joint [14]. The exact pathogenic mechanism(s)
of OA are still unknown, despite modern advances in analysis and diagnosis [20], which accounts
for the pre-clinical and clinical failure of a number of potential disease-modifying pharmacological
therapies [21].
Articular cartilage has a relatively simple tissue composition of only a single cell type, chondrocytes,
encased in an abundant ECM, in the absence of blood vessels, nerves, or lymphoid tissue. Any change
in its components affects cartilage homeostasis. As the cartilage ECM is produced by chondrocytes, OA
pathogenesis is therefore frequently linked to changes in chondrocyte activities, including proliferation,
matrix deposition, inflammatory cytokine production, and response to signaling molecules. These
changes drive cartilage degradation and therefore represent candidate therapeutic targets to reverse
OA and maintain articular cartilage integrity. We have summarized in this review updated findings
on OA pathology, related molecular mechanisms, traditional experimental models, and novel OA
models represented by human cell-derived microphysiological systems, to inform future basic and
translational OA research.
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2. Risk Factors
The known risk factors of OA include aging, obesity, genetic predisposition, acute trauma and
chronic overload, gender and hormone profile, and metabolic syndrome [22,23] (Figure 1). However, it
should be noted that OA is not the inevitable consequence of these factors. In addition, the different
risk factors may act together in the pathogenesis of osteoarthritis. For example, in older adults with
anterior cruciate ligament tear, OA develops faster than in younger adults [24].
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Aging, characterized by the progressive loss of tissue and organ function over time, represents
the single greatest risk factor for OA [25]. The Framingham Osteoarthritis Study has established
that the frequency of ra iographically ev d nt OA, i.e., joint space arrowing, increas s with each
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over tim that eventually leads to cellular defects and tissue dysfunction, resulting in increased frailty
and age-related diseases [27,28]. Sources of this d mage r primarily react ve oxygen and nit ogen
species produced by mitochondria and cellular stre s resp ses, respectively. The proximal effect
of th se reactive oxygen speci (ROS) is the accumulation of somatic mutations and DNA damage,
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changes reduce the ability of chondrocytes to main cartilage homeostasis and lower the threshold of
damage-inducing load [29]. A wide range of antioxidants have proven effective in reducing induced
OA in animal models, including cyclooxygenase-2 (COX-2) inhibitors, hyaluronic acid (HA) and
glucosamine, interleukin-1β (IL-1β) receptor antagonists, and polyphenols [30]. As many of the
ROS are produced by inefficient mitochondria and radical scavenging, increasing mitochondrial
efficiency through the induction of mitophagy (recycling of damaged mitochondria) is the most
recent therapeutic target under investigation (Figure 1) [31,32]. Cellular senescence, a phenomenon of
irreversible cell growth arrest, is a common cellular outcome of aging (time), and is highly correlated
with ROS-induced DNA damage and protein/lipid peroxidation that result from excess ROS (oxidative
stress) [33]. Chondrocytes from older adults are shown to exhibit many of the changes typical of cell
senescence, such as increased senescence-associated β-galactosidase (SA-β-Gal) activity, enhanced p16
expression, and decreased mean telomere length [34,35]. Interestingly, individuals with OA display a
significantly higher number of senescent cells within their cartilage, thus driving elevated expression
of detrimental factors that contribute to cartilage degeneration, including IL-1β [35,36], IL-7 [37], and
matrix metalloproteinase-13 (MMP-13) [38,39]. However, the exact contribution of aging-associated
chondrocyte senescence to OA pathogenesis requires further investigation.
2.2. Trauma
Traumatic injury often causes joint instability or intraarticular fractures, causing post-traumatic
osteoarthritis (PTOA). Joint injury results in abnormal loading vectors and increased contact stresses
that are known to be injurious to articular cartilage [40,41]. PTOA accounts for approximately 12%
of all OA [42], and weight-bearing joints are most susceptible. For example, injuries to the knee
elements, such as anterior cruciate ligament (ACL) tear and meniscal resection, result in increased
radiographic OA occurring at an earlier age [43]. It is estimated that PTOA results in 21% of patients
after ACL transection injury, which increases to 48% in those with concomitant meniscal injury [43].
In comparison, 70–80% of radiographic ankle OA cases are of post-traumatic origin, with most patients
being younger than those with primary ankle OA [44]. The principal consequences of trauma to
the articular cartilage are an immediate loss of cells through necrosis and apoptosis and subsequent
increased production of ROS and nitric oxide synthases (NOS) [45]. Early intervention strategies
focused on the reduction of cell loss through inhibitors of NOS and apoptosis, and the inhibition of
catabolic enzymes such as MMPs and aggrecanase [46]. Newer methods aim to promote anabolic
processes through modulation of fibroblast growth factors (FGFs) and WNT signaling and inhibition
of hypertrophy [47]. A promising recent reagent is SM04690 (Samumed), an inhibitor of WNT receptor
binding that is now in a phase III clinical trial, which has been shown to elicit protective effects on
cartilage during joint destruction in an acute cruciate ligament tear and partial medial meniscectomy
rodent OA model [48]. Inhibition of β-catenin, an intracellular signal transducer of WNT, by StAx-35R
inhibits chondrocyte phenotypic shifting of human OA cartilage explants, and has been reported to
result in increased SRY-Box transcription factor 9 (SOX9) and aggrecan gene expression and decreased
collagen type X α1 chain (COL10A1) gene expression [49,50].
2.3. Obesity
Obesity, defined as a Body Mass Index (BMI) greater than 30 kg/m2, has become a worldwide
problem of epidemic proportions. Mechanically, the force exerted on the knee when walking is three to
six times one’s body weight, thus a higher body weight significantly increases joint contact stresses [51].
A recent meta-analysis reports an odds ratio (OR) of 1.98 (95% CI 1.57e2.20) and 2.66 (95% CI 2.15e3.28)
for developing knee OA in overweight and obese patients, respectively [52]. In contrast, weight
loss significantly decreased the risk for the development of knee OA. According to a Framingham
study on women, a decrease in body mass index of 2 units or more (weight loss of approximately
5.1 kg) over the 10 years before the designated examination decreased the odds for developing OA by
over 50% [53]. In addition to the physical effects, obesity is associated with an increase in systemic
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metabolic inflammation, and is a risk factor of metabolic syndrome (MS) [54]. Population-based studies
conducted in Japan, Nigeria, Egypt, and China have shown that the accumulation of MS components,
such as hypertension, dyslipidemia, and impaired glucose tolerance, is strongly correlated with the
presence of knee OA and associated advanced radiographic changes, severe pain, and increased
functional impairment score [55–58]. Therefore, the connection between obesity and OA is attributed
to not only mechanical loading and “wear-and-tear” at the cartilage surface, but also metabolic and
inflammatory mediators, specifically degradative enzymes and adipose tissue-derived cytokines
(known as adipokines) [59,60]. Some adipokines, such as leptin, adiponectin, and lipocalin 2, among
others, induce production of inflammatory cytokines, including tumor necrosis factor alpha (TNF-α),
interleukin (IL)-6, and C-X-C motif chemokine ligand 5 (CXCL5), thus resulting in cartilage matrix
damage and subchondral bone remodeling [61]. It is thus not surprising that diets rich in saturated
fat have been reported to weaken cartilage metabolism and increase joint damage, leading to OA
development. Correlations between high-fat diet and osteocyte changes have also been reported [62].
2.4. Chronic Mechanical Overloading/Overuse
Chondrocytes are continuously subjected to physiologic mechanical loading, which is essential
for maintaining a homeostatic balance between the catabolic and anabolic processes, mediated
via the suppression of proinflammatory cytokines and inflammatory mediators, enhancement of
anti-inflammatory signaling, and reduction of the activity of matrix-degrading enzymes [63]. On the
other hand, supraphysiological loading has been known to skew this balance towards catabolic processes
that lead to cartilage defects, bone marrow lesions, subchondral sclerosis, cartilage thinning, and OA
onset [11,64–66]. In an ex-elite female athlete study, weight-bearing sports activity was associated with
a 2–3-fold increase in radiologic OA risks [67]. Another workload study found that long-term heavy
lifting or extended periods of standing at work are associated with hip OA [68]. It should be noted that
physiological loading in vivo varies greatly based on anatomical location and history [69], and the area
with more cartilage loss is often associated with higher mechanical loading [70]. The chondroprotective
effect of physiological mechanical loading is in part achieved through the mechanotransduction
mechanisms, such as mechanosensitive ion channels of transient receptor potential vanilloid 4 (TRPV4),
and signaling via integrins and primary cilia [69]. For example, under moderate dynamic loading,
TRPV4-mediated Ca2+ signaling enhances matrix biosynthesis and decreases the expression of catabolic
and proinflammatory genes via regulating multiple signaling pathways, including those involving
nuclear factor of activated T lymphocytes (NFAT), protein kinase C, NF-κB, JNK1, and cyclic adenosine
monophosphate (cAMP) response element-binding protein (CREB) [71]. The signaling pathways
involved the degenerative process are, on the other hand, less understood. Available studies show
that abnormal mechanical stress may increase the production of proinflammatory mediators, such
as prostaglandin E2 (PGE2) and nitric oxide (NO), and proinflammatory cytokines, such as IL-1β
and TNF-α, that act together to affect cartilage metabolism in multiple ways [65]. Mitogen-activated
protein kinase (MAPK), activator protein 1 (AP-1), and NF-κB signaling pathways participate in the
upregulation of PGE2 and IL-1β-induced NO release [72]. COX-2 could be induced by high intensities
of fluid shear stress through the Rac/MEKK1/MKK7/JNK2/c-JunC/EBP pathway [73]. In addition,
mechanical injury can cause mitochondrial dysfunction [74], such as the imbalance of superoxide
and superoxide dismutase 2 (SOD2), thus resulting in cartilage degeneration [75]. Further research is
needed to reveal the molecular mechanisms underlying excessive mechanical loading-induced OA
and propose treatment strategies targeting this risk factor.
2.5. Genetics
OA is considered a multifactorial polygenic disease that is influenced by multiple genetic
and environmental factors [76]. Inheritance studies involving family groups and twin pairs have
demonstrated that 39–78% of OA cases can be attributed to genetic factors [77,78]. In addition to directly
causing OA, mutations in certain genes could also determine the age of disease onset, sites of affected
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joints, as well as the severity and progression rate of OA [78]. Most established OA-associated variants
are represented by common single-nucleotide polymorphism (SNP) with minor allele frequencies
(MAF) > 5% that have moderate to small effect sizes (OR: ~1.1–1.3) [79]. Genome-wide association
studies (GWAS) are powerful tools capable of examining hundreds of thousands of SNPs across
the genome to establish associations between genetic factors and the risk of complex diseases and
traits [80]. By the end of 2019, 90 genome-wide significant OA risk loci have been identified with GWAS,
most of which are enriched near genes involved in skeletal development and morphogenesis [81,82].
These include the Wnt pathway genes HBP1 (HMG-Box transcription factor 1) and BCL9 (B cell
CLL/lymphoma 9 protein), and TGFβ pathway genes TGFB1, latent transforming growth factor beta
binding protein 1 (LTBP1), LTBP3, SMAD3, and the recently identified ROCR long non-coding RNA
(lncRNA) that acts upstream of SOX9 during chondrogenic differentiation [83–85]. Genetic overlaps
with height, hip shape, bone area, and developmental dysplasia of the hip are observed in these
sensitive loci, which might alter joint biomechanics and predispose the individual to OA later in
life [86,87].
3. Regulatory Pathways
Although how the risk factors may be translated into pathogenic mechanisms is not known, there
are a number of signaling and/or regulatory pathways (Table 1) and molecules such as microRNAs and
lncRNAs that have been shown to play important roles in articular cartilage mediating the activities
of chondrocytes (Figure 2). It should be emphasized that some regulatory pathways have a clearly
defined role, either catabolic or anabolic, while others, such as those involving Wnt, may mediate
protective or degenerative activities as a function of the state of tissue health.
3.1. Wnt/β-Catenin Signaling
Wnts are a family of extracellularly secreted glycoproteins that are involved in numerous biological
activities, including cell proliferation, differentiation, polarization, and fate determination; in addition,
Wnts have been implicated in the occurrence and development of some diseases via canonical
β-catenin-dependent and noncanonical β-catenin-independent signaling pathways [47]. During
cartilage development, Wnt/β-catenin signaling activity is strictly regulated in chondrogenesis and
chondrocyte maturation [88]. In the adult articular cartilage, excessive Wnt pathway activation under
IL-1β stimulation is thought to be an OA progression susceptibility factor and is commonly used to
establish an OA model [89]. Increased expression of Wnt pathway activator Wnt1-inducible-signaling
pathway protein 1 (WISP-1) is found in both murine and human OA tissues to induce articular
cartilage degradation via upregulating the expression of MMPs and aggrecanases in chondrocytes
and macrophages [90]. The expression levels of some Wnt pathway antagonists, such as sclerostin,
dickkopf WNT signaling pathway inhibitor 1 (DKK1), and secreted frizzled-related protein 3 (sFRP3),
may decrease in parallel with OA progression. Upregulating the expression of these antagonists
alleviates OA cartilage destruction [91–93]. Potential drugs that selectively inhibit the Wnt pathway,
such as SM04690, an inhibitor of intranuclear kinases CDC-like kinase 2 (CLK2) and dual-specificity
tyrosine phosphorylation-regulated kinase 1A (DYRK1A), or XAV-939, a tankyrase inhibitor, have
been shown to be effective in preclinical studies and clinical trials [48,94,95]. However, recent studies
revealed a dual role of the Wnt pathway in OA development which deserves attention. Zhu et al. found
enhanced articular cartilage destruction in transgenic mice expressing an inhibitor of β-catenin and Tcf
in chondrocytes [96]. In the superficial zone of cartilage in adult mice, highly expressed Wnt ligands
and stabilized β-catenin upregulate Prg4 expression, which then suppresses cartilage degeneration [97].
In addition, Theologis et al. found that DKK1 was upregulated in knee synovial fluid (SF) and serum of
OA patients, showing positive correlation with OA severity [98]. These results reveal the importance of
WNT signaling in maintaining the normal function of chondrocytes and suggest a potential detrimental
effect of Wnt inhibitor-based DMOADs on articular cartilage homeostasis and OA progression [96,99].
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More research is thus needed to elucidate the role of this pathway. In particular, a better, controlled
strategy to fine-tune the spatiotemporal expression of β-catenin is necessary.
3.2. PI3K/Akt/mTOR Pathway
The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin
(mTOR) signaling pathway participates in cell cycle regulation, and is directly related to cellular
quiescence, proliferation, cancer, and longevity [100,101]. It also participates in ECM catabolism,
anabolism, and chondrocyte homeostasis via regulation of gene expression of MMPs, collagen type II,
aggrecan, and a dis-integrin and metalloproteinase with thrombospondin motifs (ADAMTS) [102,103].
A GWAS report found that putative AKT1 rs2498789 and PIK3CA rs7646409 functional variants
were associated with knee OA susceptibility in the Chinese Han population [104]. Results from an
in vivo study showed that suppression of PI3K/AKT/mTOR signaling pathway promotes chondrocyte
autophagy and attenuates the inflammatory response in OA rats [105]. Introduction of pro-autophagic
γ-aminobutyric acid receptor-associated protein (GABARAP) to an OA rat model was shown to promote
bone marrow mesenchymal stem cell (MSC)-based repair of OA cartilage through the inhibition of
PI3K/AKT/mTOR signaling [106]. Several agents targeting the AKT pathway have proven effective in
reducing articular cartilage destruction in animal models, providing potential therapeutic agents for
the treatment of human OA [107–109].
3.3. Notch Signaling Pathway
Notch receptors are large single-pass transmembrane proteins that regulate differentiation and
apoptosis during embryogenesis and postnatal development through binding to transmembrane
ligands expressed on adjacent cells [110,111]. The consequence of Notch signaling can be attributed
to different potential Notch receptors, different subcellular locations, and crosstalk between Notch
signaling and other signaling pathways [112]. Notch signaling has been clearly shown to play an
important role in synovial joint development [113–116]. In fact, Notch is proposed as a marker of
cartilage progenitor cells [117,118]. In the development of mouse limb, intracellular domains of Notch1
and -2 are translocated into the nucleus of chondrocytes to promote their terminal differentiation [118].
However, regarding the exact role of Notch in cartilage hemostasis and OA, apparently contradictory
results have been reported in different studies. For example, both Notch signaling activation [118,119]
and inhibition [120,121] have been shown to contribute to OA development. However, there is more
evidence supporting the pro-degeneration role of Notch signaling in OA pathogenesis. For example,
a primary locus in Notch control of cartilage hypertrophy and OA is the transcription factor HES1
(Hes family BHLH transcription factor 1), which appears to act via the intracellular transduction
molecule RPBJ (recombination signal binding protein for immunoglobulin kappa J region) to induce
common OA-associated genes, including MMP-13, ADAMTS5, and IL-6, among others [110]. Moreover,
intraarticular injection of a Notch inhibitor was reported to prevent the development of knee OA in
mice [118]. Further studies are needed to comprehensively understand the Notch signaling pathway
in the molecular network that regulates cartilage homeostasis and OA pathogenesis.
3.4. SIRT1/AMPK Pathway
Sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK), two critical sensors that regulate
mitochondrial biogenesis and oxidative capacity, have been recognized as therapeutic OA targets [122].
Homocysteine-reduced SIRT1 leads to phosphorylated AMPK and peroxisome proliferator-activated
receptor-gamma coactivator (PGC)-1α downregulation, leading to oxidative stress and mitochondrial
dysfunction. These homocysteine-induced changes, along with proapoptosis effect, can be reversed
by activating SIRT1/AMPK/PGC-1α signaling [123]. Animal studies show that quercetin attenuates
oxidative stress-induced apoptosis and mitochondrial dysfunction via upregulated AMPK/SIRT1
signaling pathway in chondrocytes, thus preventing OA progression in murine models [124,125].
In a human study, transcription factor A mitochondrial (TFAM)-mediated activation of the
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AMPK/SIRT-1/PGC-1α pathway could reverse the deficiency of mitochondrial biogenesis in human
OA chondrocytes, suggesting the potential of pharmacologic AMPK activators in mitigating OA
progression [126].
3.5. Hippo Pathway-YAP/TAZ Signaling
The Hippo signaling pathway is a conserved organ size regulator that acts by controlling cell
proliferation and apoptosis [127]. Central to this pathway is a kinase cascade leading from the tumor
suppressor Hippo (Macrophage Stimulating 1 (Mst1) and Mst2 in mammals) to the oncoprotein
Yki (yes-associated protein 1 (YAP) and tafazzin (TAZ) in mammals) [128]. Although the exact
role of the Hippo pathway in cartilage protection and OA development is unclear, the majority
of studies show that YAP is a protective effector. For example, YAP was found to cooperate with
TEA domain transcriptional factor (TEAD) and activate forkhead box D1 (FOXD1) expression, thus
alleviating chondrocyte senescence and OA [129]. In a murine OA model, YAP activation by transgenic
overexpression or deletion of the upstream inhibitory kinase Mst1/2 binding sites preserves articular
cartilage integrity, whereas downregulation of YAP by inflammatory cytokines through TAK1-mediated
phosphorylation promotes cartilage disruption [130,131]. Furthermore, YAP directly interacts with
TAK1 and NF-κB signaling by inhibiting substrate TAK1 accessibility and reducing NF-κB-induced
matrix-degrading enzyme expression and cartilage degradation during OA pathogenesis [130].
On the other hand, other studies hold that YAP activity increases catabolic gene expression in
response to IL-1β. siRNA-mediated suppression of YAP has been shown to inhibit IL-1β stimulated
catabolic gene expression, prevent cartilage degradation, and ameliorate OA development. This is
supported by the observation in a murine OA model that conditional knock-out (cKO) of YAP preserves
collagen type II expression and protects cartilage from degeneration [132]. In fact, intraarticular injection
of YAP siRNA was shown to ameliorate OA development in mice [133]. Recently, YAP has also been
shown to dictate chondrocyte responses to substrate stiffness. For example, chondrocytes cultured on
soft surface display higher collagen type II expression than those on stiff surface, accompanied by lower
expression and predominantly cytoplasmic localization of YAP [134]. In addition, knock-out of YAP
significantly enhances collagen type II expression in chondrocytes seeded on stiff substrate. Finally,
YAP is believed to negatively regulate chondrogenic differentiation of MSCs, while chondrogenic
signaling de-repression requires YAP downregulation [135]. The exact role(s) of YAP in OA initiation
and/or progression awaits further investigations.
3.6. Disruptor of Telomeric Silencing 1-Like (DOT1L) Pathway
Epigenetic modifications are chemical or physical changes in chromatin that control gene
transcription and translation without changing DNA sequence. These modifications include, but
are not limited to, DNA methylation, histone modification, chromatin remodeling, and regulatory
noncoding RNAs (ncRNAs) [136]. DOT1 is an evolutionarily conserved histone methyltransferase
which is involved in epigenetic gene transcription regulation via methylation of lysine-79 of histone H3
(H3K79) [137]. GWAS results have shown that DOT1L safeguards cartilage homeostasis and protects
against OA [138]. Maintaining or enhancing DOT1L activity during aging or after trauma might
prevent OA onset and progression [139], while DOT1L loss disrupts molecular signature in healthy
chondrocytes and increases susceptibility to develop spontaneous and post-traumatic OA in mice [140].
Unexpectedly, the protective function of DOT1L is attributable to inhibition of Wnt signaling by
inhibiting the activity of SIRT1 [139], which is generally seen as a protective factor for chondrocytes
(see above). More research is needed to verify this finding. In addition to affecting cartilage, DOT1L
seems to have an influence on synovial membrane as well. Synovial tissues of OA and RA patients
show increased expression of DOT1L at both transcriptional and translational levels, along with the
demethylation of its downstream H3K79 target [141]. Given its demonstrated association with OA,
epigenetics-based strategies targeting the DOT1L network could be a novel therapeutic option for OA
treatment; however, epigenetic modifications are regulated in an extremely complex network and
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other roles of DOT1L and its targeted genes are largely unknown. Thus, the regulation of DOT1L
activity and the functional consequences of manipulation of DOT1L need to be further elucidated
before efficient treatments can be developed.
Table 1. Regulatory pathways mediating chondrocyte functions.
Pathway Cells Studied Effects Ref.
Wnt/β-catenin
• Mouse and human
OA tissues • Upregulates MMPs and aggrecanases [90–94]
• Mouse
knee chondrocytes • Suppresses cartilage degeneration [97,98]
PI3K/Akt/mTOR • Rat chondrocytes
• Suppresses PI3K/Akt/mTOR promotes cartilage
repair and attenuates inflammatory response [105,106]
Notch • Mouse
knee chondrocytes
• Induces OA-associated genes and promote OA [110,118,119]
• Required for articular cartilage and joint maintenance [120,121]
SIRT1/AMPK
• Human and rat
knee chondrocytes
• Prevents OA progression by attenuating apoptosis
and mitochondrial dysfunction [123–126]
Hippo/YAP/TAZ
• Human and rat
knee chondrocytes
• Alleviates chondrocyte senescence and reduces
matrix-degrading enzyme and cartilage degradation [129,130]
• Rat knee chondrocytes
and human MSCs
• Suppresses YAP, preserves collagen type II
expression, promotes chondrogenic differentiation of
MSCs, and ameliorates OA development
[132–135]
DOT1L
• Mouse and human
knee joints
and chondrocytes
• Prevents OA onset and progression [139–142]
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stability and translation of message RNA (mRNA) via binding to the 3′-untranslated region (3′-UTRs)
of specific target genes [142]. Preventing miRNA biogenesis results in skeletal growth defects and
premature death, while specific miRNA deletion might be helpful for treating certain diseases [143].
Swingler et al. recently reviewed and summarized the role of RNAs and their targets on chondrogenesis,
chondrocyte differentiation, metabolism, apoptosis, senescence, matrix degradation, as well as OA
inflammation [144]. Here, we briefly introduce some of these microRNAs. MicroRNA-34a (miR-34a)
was the first miRNA linked to chondrocyte apoptosis. miR-34a was upregulated in human OA
cartilage, causing OA progression through delta-like protein 1 (DLL1) and PI3K/AKT pathway
modulation [145]. miR-34a also induced cell apoptosis via targeting SIRT1, contributing to chondrocyte
death. miR-24 suppresses the cell cycle inhibitor P16INK4a, a senescence marker that is increased in
OA and in terminal chondrogenesis [146]. miR-495 was overexpressed in human OA cartilage, causing
chondrocyte apoptosis and senescence by directly targeting AKT1 and the S6 mTOR system [147].
Other miRNAs related to OA include miR-335-5p [148], miR-107 [149], miR-140-3p [150], miR-223 [151],
miR-146a [152], miR-128a [153], miR-27b [154], miR-21-5p [155], and miR-149 [156]. miRNAs clearly
play a wide range of important roles in regulating chondrocyte and cartilage hemostasis, but their
short half-life, degradation susceptibility, and high mismatch rate limit clinical applications of targeting
miRNA [157].
3.8. LncRNAs
LncRNAs are defined as long RNA transcripts with lengths exceeding 200 nucleotides that
do not encode proteins [158]. LncRNAs have been demonstrated to influence gene expression
through transcriptional and translational regulation by recruiting chromatin modification factors,
influencing nuclear architecture, acting as decoys or sponges for microRNAs, and modulating the
translation and/or stability of mRNAs and proteins [158–161]. LncRNAs are functionally involved
in the entire lifespan of chondrocyte from chondrogenesis to conversion to an OA phenotype. For
example, lncRNA differentiation antagonizing non-protein coding RNA (DANCR) regulates both the
miR-1305-Smad 4 and miR-216a-5p-JAK2-STAT3 axes, which promote chondrogenic differentiation
of human synovium-derived MSCs and stimulate OA chondrocyte proliferation and apoptosis,
respectively [162,163]. LncRNA ZBED3-AS1 promotes zbed3 expression, which activates Wnt/β-catenin
signaling and promotes chondrogenesis by human synovium-derived MSCs [164]. LncRNA-HIT
(HOXA transcript induced by transforming growth factor (TGF)-β) functions in chondrogenesis as an
epigenetic regulator through recruitment of the p100/CBP (customs and border protection complex).
Suppressing lncRNA-HIT reduces mesenchymal cell condensation and cartilage nodule formation,
impairing chondrogenesis in limb bud mesenchyme [165]. LncRNA-ROCR promotes SOX9 expression
and chondrogenic differentiation [83]. In terms of disease progression, over 20 different lncRNAs
have been identified in regulating ECM degradation, chondrocyte viability, immune response, and
angiogenesis that are critical to OA pathogenesis [166]. For example, increased levels of six lncRNAs
(HOTAIR (HOX transcript antisense RNA), GAS5 (growth arrest specific 5), PMS2L2 (PMS1 homolog 2
mismatch repair system component pseudogene 2), RP11-445H22.4 (Clone-based (Vega) gene), H19 (H19
imprinted maternally expressed transcript), and CTD-2574D22.4) are associated with the upregulation
of MMP-9, MMP-13, and BMP-2 expression in OA cartilage [167]. LncRNA gastric cancer-associated
transcript 3 (GACAT3) was highly increased in OA synoviocytes (OAS). Downregulating GACAT3
expression with siRNA arrested cell cycle in G0/G1 phase and increased OAS apoptosis rate, which are
mediated by interleukin-6/signal transducer and activator of transcription-3 (IL-6/STAT3) signaling
pathway [168]. LncRNA-HOTAIRM1 variant 1 downregulation contributes to OA via regulating
the miR-125b/BMPR2 axis and activating the JNK/MAPK/ERK pathway [169]. Because lncHIFCAR
is upregulated in OA tissues, lncHIFCAR suppression may improve hypoxia-induced cell injury
via positively regulating HIF-1α and HIF-1α target genes [170]. Zinc finger antisense 1 (ZFAS1)
expression is downregulated in OA chondrocytes, therefore ZFAS1 overexpression promoted the
viability, proliferation, migration, and inhibited OA chondrocyte apoptosis and matrix synthesis by
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decreasing Wnt3a factors [171]. At present, no therapy targeting lncRNA has been approved by
regulatory bodies [172]. More investigations are needed to warrant lncRNA as a potential therapeutic
target to treat OA before conducting clinical trials.
The protective effects include anti-inflammation, anti-vascularization, antioxidation,
anti-hypertrophy, antiapoptosis, anti-dedifferentiation, and promotion of cartilage formation and
proliferation. The destructive effects typically lead to inflammation, hypertrophy, dedifferentiation,
accelerating senescence, apoptosis and ossification, and so on. It is noteworthy that some factors
and pathways may display protective or destructive functions dependent on different physiological
states. AKT: RAC-alpha serine/threonine-protein kinase; AMPK: 5′ AMP-activated protein kinase;
DOT1L: Disruptor of telomeric silencing 1-like; mTOR: Mammalian target of rapamycin; PI3K:
Phosphatidylinositol 3-kinase; SIRT1: Silent information regulator 1.
4. Experimental Models
Experimental models are critical for the study of human diseases. Various in vitro and in vivo
models have been established throughout the years to mechanistically understand OA pathologies
and develop effective therapies. The translational value of the models is determined by how closely
they functionally align with the pathogenesis and progression characteristics of the disease.
4.1. In Vivo Models
The OA risk factors discussed above have been recapitulated in different types of animal models
(Table 2). No single animal model can mimic all features of human OA and predict all the clinical
responses to drugs [173]. Therefore, it is important to note that currently available OA models only
cater to a specific mechanism or feature of disease etiology or pathogenesis observed in OA patients.
Collectively, the in vivo OA models have significantly advanced our understanding of the disease and
its treatment regimen.
4.1.1. Aging-Induced Spontaneous OA Models
Aging is among the highest risk factors for OA. In older adults, OA is the most common cause of
limited mobility and compromised quality of life. Spontaneous OA development has been observed in
mouse strains including C57/BL6 and STR/Ort mice [174,175]. The time required for mice to develop
spontaneous OA phenotypes is much longer than in PTOA models. Wilhelmi et al. [174] reported a
high OA incidence of 39–61% in 17-month-old C57/BL6 mice, and only a 19% incidence for those aged
15.5 months. The STR/Ort mice are known to be OA-prone and require a relatively short 12–20-week
period to develop OA [175,176]. Articular cartilage degeneration during chronological aging-induced
OA development was found to be closely related to the NF-κB signaling pathway in STR/Ort mice [174].
Aging-associated spontaneous OA model has also been established in other species. For example,
Dunkin Hartley guinea pigs display higher OA severity with increasing age, reaching moderate to
severe OA at 18 months [177]. Spontaneously occurring OA generally appears at a much older age in
large animals, such as commercial pig and rhesus macaque [178,179].
4.1.2. Trauma-Induced OA Models
In trauma-induced models, an injurious event, typically instability caused by disrupted joint
mechanics, precedes joint arthritis pathogenesis. This trauma can be introduced either invasively or
noninvasively. Destabilization of the medial meniscus (DMM) is a well-established and commonly used
surgical model where, typically, the medial meniscotibial ligament (MMTL) is transected. As a result,
the medial meniscus is displaced medially during activity. This displacement induces abnormal contact
stress in the opposing cartilage surfaces which is hypothesized to cause the increase in OA observed
clinically after meniscus injury or meniscectomy. The DMM surgery control is usually conducted
following the same procedure but without MMTL transection. In the 129/SvEv mouse model, a
common background in the production of targeted mutations, mild-to-moderate OA symptoms were
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observed at 4 weeks post-surgery, and moderate-to-severe OA symptoms were seen at 8 weeks [180].
However, subchondral bone lesions were not observed in this DMM mouse model. Other surgical
procedures to induce joint trauma include anterior cruciate ligament transection (ACLT) [181] and
partial or total meniscectomy [182]. The ACLT model was the earliest developed OA model that was
intended to replicate the degradation of articular cartilage after ACL rupture in humans. However, it
is now accepted that this model is unlikely directly comparable to injury in human knee joints [183].
Specifically, immediate and severe joint instability after ACLT leads to the rapid development and
progression of OA in animal models, which does not reflect the clinical scenario in human OA [184].
Besides mice and rats, large animals have also been used to generate PTOA models. Using
4-year-old wethers, Cake et al. [185] compared the well-established meniscectomy model with two
less traumatic procedures on the meniscus—mid-body transection and cranial pole release—and
found that the two new, simpler procedures resulted in similar primary pathological outcomes 3
months post-surgery.
A number of non-surgical PTOA models have been introduced in the past decade, eliminating
the confounding effects of invasive injurious procedures [186]. In all these models, the skin or joint
capsule of the mice is not disrupted, making the procedure entirely aseptic. In general, noninvasive
PTOA models are generated by (1) intraarticular fracture (IAF) of the tibial plateau [186,187], (2) tibia
compression of articular cartilage [188,189], or (3) ACL rupture by tibia compression overload [190].
As an example, a custom cradle and an indenter were employed to create closed, intraarticular tibia
plateau fracture in the mouse knee, which resulted in OA-like pathological changes in both articular
cartilage and subchondral bone [187]. In addition to cartilage degeneration, rapid trabecular bone loss
and subsequent partial recovery, as well as considerable bone malformation in the joint space, were
also observed following injury.
In previous studies, we reported a portable spring-loaded impactor designed to deliver traumatic,
energy-controlled impacts on articular cartilage [191,192]. Using this maneuverable device, we created
a first-of-its-kind, injury-induced OA model by subjecting the medial femoral condyle articular cartilage
of rabbits to supraphysiological impact. OA characteristics of focal cartilage degeneration, including
cell death, tidemark remodeling, loss of cells, and cartilaginous matrix, could be observed for up to 3
months after a single 0.28 J impact was delivered by this impactor [45]. This impact model was later
adopted for generating OA-like syndrome in horses [74].
4.1.3. Obesity-Induced OA Models
Higher OA incidence in obese people is attributed to not only excessive joint loading caused by
increased body weight, but also the associated systemic inflammation, dysregulated lipid metabolism,
and altered adipokine profile [193,194]. Mice fed with a high-fat diet (HFD) exhibit higher levels of
proinflammatory cytokines, including IL-1β, IL-6, IL-8, IL-13, leptin, and TNF-α; also present at higher
levels in these mice are proteins involved in cartilage metabolism, such as TGF-β1, MMP-13, and
vascular endothelial growth factor-α (VEGF-α) [195].
Griffin et al. [196,197] found that HFD (60% kcal from fat, as compared to 10–13.5% from fat
for normal diet) caused early-stage knee OA in C57BL/6J mice. Furthermore, researchers observed
alleviated OA symptoms in mice that underwent voluntary wheel running, suggesting that higher
joint loading per se does not suffice to explain the increased OA incidences in the obesity models [197].
Mice with high-fat-induced obesity have also been used to undergo joint injury, generating PTOA
models [198,199]. In addition to accelerated development of age-related spontaneous OA, mice fed with
HFD also displayed more severe articular cartilage degeneration in DMM-induced OA as compared
with mice fed with lean diet [200]. Underlying the higher OA susceptibility for HFD-fed mice were
elevated leptin levels in their plasma and articular cartilage as well as a distinct, longitudinal plasma
profile characterized by higher levels of phosphatidylcholines and lysophosphatidylcholines [200].
Schott et al. created a PTOA model in C57BL/6J mice with HFD-induced obesity, and found that the
gut microbiome can be targeted to curb systemic inflammation and thus treat OA in obese mice [198].
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It should be noted that while previous studies revealed unequivocally that HFD caused exacerbation
of PTOA, inconsistent results have been observed in regard to the ability of HFD in OA induction in
mouse models [195].
4.1.4. Chemically Induced OA Models
Several chemicals, including monosodium iodoacetate (MIA), papain, collagenase, and quinolone,
have been proposed to induce OA in animal models, with MIA being the most commonly used chemical
agent to induce OA in mouse and rat models [201–204]. MIA inhibits glyceraldehyde-3-phosphate
dehydrogenase activity, resulting in rapid and widespread chondrocyte death [205]. OA rat models
are typically generated by a single intraarticular injection of 100–1200 µg MIA, usually dissolved in
physiological saline [201,205–207]. Rapid disease progression can be observed after intraarticular
MIA injection. Typically, chondrocyte degeneration and necrosis can be observed as early as 1–7 days
post-injection, and subchondral bone changes are noted by day 7.
It should be noted that many MIA-induced pathological changes in mice and rates are not typical
of human OA. Transcriptional profiling and pathway analysis have revealed little similarities between
cartilage tissues from the MIA model of OA in rats and those from human OA joints [201]. Therefore,
MIA-induced experimental OA models possess limited clinical relevance and low translatability to
human disease. Other OA-inducing chemicals include collagenase and quinolone [203,204]. In general,
because of the low clinical relevance of chemical injury-caused pathophysiology, chemically induced
models are less popular in OA research.
4.1.5. OA Models Involving Genetic Manipulations
Genetically modified models for OA research are predominantly established in mice because of their
short life cycle, high fecundity, breeding efficiency, and being amenable to genetic manipulations [208].
They bear general biological similarities to humans, as reflected in physiology and disease pathogenesis.
In particular, the genetic homology between mice and humans presents a useful model to investigate
the genetic components of human diseases [209]. A number of genetic modifications have recently
been made to target different OA characteristics, such as cartilage matrix degeneration [210],
inflammation [211], and chondrocyte hypertrophy and apoptosis [118]. Wang et al. [212] studied mice
genetically deficient in complement component 5, and found reduced expression of proinflammatory
cytokines and degradative molecules in chondrocytes from joints destabilized by medial meniscectomy,
compared to wild type animals. In addition, knock-out of chondrocyte-specific Epas1, the gene
encoding the signaling molecule hypoxia-inducible factor (HIF)-2α, in mice resulted in inhibition of
chondrocyte apoptosis and cartilage destruction in the DMM models of OA [213].
Genetically manipulated animal models produced by gene knock-in and knock-out approaches
have been studied to elucidate the protective or destructive role of specific molecules. For example, in
Mmp-13-knock-out mice, structural cartilage damage was inhibited in surgically induced OA [214].
Neuhold et al. [215] generated Mmp-13 transgenic mice with cartilage-specific overexpression of
Mmp-13 and observed pathological changes, such as articular cartilage degeneration and synovial
hyperplasia, that strongly resemble human OA phenotypes. These loss- and gain-of-function studies
clearly indicated the detrimental role of MMP-13 in OA pathogenesis. A small mutation deletion
in collagen type II (Col2a1) gene was found to result in spontaneous, early-onset articular cartilage
degeneration in transgenic Del1 (+/−) mice [216]. Similarly, Col9a1−/−mice, a strain deficient in collagen
type IX, experienced faster, spontaneous OA-like changes in the knee joints than their wild type
littermates [217]. ADAMTS-4 and ADAMTS-5 have both been recognized as enzymes responsible
for aggrecan degradation, a key contributing factor to the degradation of OA cartilage [218]. While
knocking out of Adamts-4 in mice did not reduce aggrecan loss or slow down the progression of surgically
induced OA [219], Adamts-5-knock-out mice showed significant reduction in cartilage destruction
after DMM surgery [220], revealing their different roles in cartilage degeneration. Little et al. [221]
generated heterozygous C57BL/6 aggrecan knock-in mice, and this genetic modification protected the
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mice against cartilage degradation in both PTOA and inflammatory arthritis models through inhibiting
aggrecanase-mediated cleavage of aggrecan in the interglobular domain.
Transgenic mice are also used to investigate the roles of different signaling pathways and their
associated receptors and ligands in OA development. For example, inhibition of TGF-β signaling by
chondrocyte-specific deletion of TGF-β receptor type II (Tgfβr2) in mice led to progressive articular
cartilage loss and OA-like phenotype, which was ameliorated by further deletion of Mmp13 or
Adamts5 genes, indicating that they are critical downstream target genes of TGF-β pathway [222].
Indian hedgehog (Ihh), the major hedgehog ligand in chondrocytes, was specifically deleted in
Col2a1-CreERT2 Ihhfl/f mouse cartilage, and the resultant loss in IHH signaling was found to significantly
decrease cartilage degeneration in surgically induced OA [223]. Another signaling pathway actively
researched in mutant mice is the Wnt pathway due to its critical role in postnatal joint biology and OA
development [224,225].
The use of genetically modified mouse strains, typically through the knock-in or -out of known
genes, has significantly enhanced our understanding of molecular mechanisms underlying OA
pathogenesis. Specifically, these mice are robust tools to study the upstream and downstream
network of the target genes, and the mechanistic information facilitates the identification of new
disease-modifying targets [226]. Given that OA is a whole joint disease, future studies should focus
on mouse models that have been genetically manipulated to target joint tissues other than cartilage,
including subchondral bone, synovium, and infrapatellar fat pad (IPFP), to enhance our understanding
of the joint pathologies.
Table 2. Advantages and limitations of current animal models for studying OA.
In Vivo Models Advantages Limitations Ref.
Aging-induced
spontaneous OA models
• Simulate natural progression
of OA in human
• Target one of the most
important OA risk factors
• Need long duration to induce OA
• High cost due to prolonged housing
of animals




• Fast OA initiation
and development
• Noninvasive trauma-induced
models can be created with
precision and minimum
infection risk
• More severe trauma usually applied than
common human knee injuries
• Much faster and more severe OA induction
than in human patients




• Target a key OA risk factor
• Replicate both altered joint
biomechanics and systemic
inflammation seen in obese
OA patients
• Variability caused by interactions of obesity
with genetic and environmental factors [197,200]
Chemically induced
OA models
• Ease of OA induction
• Precise control of
chemical dose
• Pathogenesis not typical of human OA
• Low translatability [204,206]
OA models involving
genetic manipulations
• Enable studies on the
protective/destructive roles of
specific genes
• Facilitate investigations into
unknown signaling pathways
in OA
• Can be combined with other
models in mechanistic studies
• High cost
• Tend to oversimplify OA pathogenesis
• Limited clinical relevance of OA induction by
a specific gene mutation
• Most reported genetic manipulations target
only cartilage
[212,214]
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4.2. In Vitro Models
While biomedical research has been greatly enhanced over the past decades with the use of
mammalian animals as a replacement for human subjects, there are also significant limitations and
disadvantages, including high costs and social and ethical issues, including the intrinsic genetic
differences between human and animals. Thus, in vitro cell and tissue cultures have been used since
the development of sterile culture techniques almost a century ago as alternatives. These models are
purposed according to the 3R principle—replacing, reducing, and refining animal work—and are
implemented to bring about more humane research. We discuss in this section both traditional and
novel in vitro OA research models, and their respective advantages and disadvantages (see Table 3).
4.2.1. Monolayer Culture
OA studies involving monolayer culture mostly employ chondrocytes, because degradation of
cartilage, in which chondrocyte is the sole cellular component, remains a predominant OA symptom.
Monolayer culture serves as a convenient platform to investigate cartilage biology under normal
or disturbed conditions. For example, cyclic strain at high magnitude and frequency was found to
result in catabolic and degenerative responses by articular chondrocytes [227,228]. To investigate
the role of mechanical stress in OA development, porcine chondrocyte monolayer cultures were
subjected to cyclic equibiaxial 10% tensile strain (0.5 Hz) [229]. At different times throughout the 24-h
period of stretching, chondrocytes showed catabolic responses such as increased expression of MMPs,
cyclooxygenases, nitrite, and prostaglandin E2. Monolayer cultures of synoviocytes have also been used
in OA studies [230,231]. To investigate cartilage–synovium crosstalk, chondrocyte-conditioned medium
was used to treat synoviofibroblasts [232]. It was found that a relatively modest chondrocyte-derived
IL-6 concentration induced a vastly higher amount of IL-6 secreted by synoviocytes from obese
OA patients than from normal-weight patients. This inflammatory response clearly indicated
chondrocyte–synoviocyte crosstalk and was further found to be enhanced by leptin, an adipokine
related to obesity [232]. Despite the relatively high reproducibility and cost-effectiveness of monolayer
cultures, there is growing consensus that a 2-dimensional (2D) plastic surface poorly mimics the in vivo
chondrocyte niche. Specifically, in 2D cultures, chondrocytes undergo a dedifferentiation process
characterized by the loss of collagen type II and aggrecan expression and increased collagen type
I expression [233], thus representing a compromised cellular phenotype. Monolayer cultures have
thus gradually fallen out of favor in recent OA studies, and are most often used as a supplement to
3D models.
4.2.2. 3D Engineered Cartilage Tissues
Recognizing that native chondrocytes reside in a 3D microenvironment, researchers have mostly
favored 3D cartilage models for in vitro OA studies. High cell density micromass cultures and pellet
cultures remain the most commonly used 3D culture approaches for engineering cartilage in vitro.
Encapsulating stem cells or primary chondrocytes in biomaterial scaffolds has also been widely
employed to create 3D cartilage tissue. In a previous study, dedifferentiated human chondrocytes at
passage 5 were redifferentiated under identical conditions in monolayer, pellet cultures, or 3D alginate
beads [234]. 3D cultures showed higher chondrogenic potential, while 2D cultures led to hypertrophic
and mineralization marker expression. In a similar study, Yeung et al. [235] found that 3D collagen
microsphere culture of human OA chondrocytes (hOACs) could better recapitulate the OA phenotypes
in vitro, as compared to 2D monolayer culture and traditional 3D pellet culture.
3D engineered cartilage tissues are frequently employed to generate inflammatory OA models.
To create an OA model, human articular chondrocytes and mouse RAW 264.7 macrophages were
separately encapsulated in 3D poly (ethylene glycol) diacrylate hydrogels and co-cultured in a Transwell
system, consisting of a semipermeable membrane to separate the two cell types cultured in the same
medium [236]. Through the culture medium shared by the two cell-laden constructs, this model was
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intended to mimic inflammatory OA features with direct the communication between cartilage and
macrophages. In another study, primary human chondrocytes were seeded on silk protein porous
scaffolds to engineer 3D cartilage tissues, which displayed OA-like phenotypes when insulted by
macrophage-conditioned medium [237].
OA models based on 3D engineered cartilage tissues can also be utilized to test potential
OA therapies. For example, an arthritic neocartilage model was generated by challenging human
chondrocyte-laden collagen scaffolds with IL-1β and TNF-α. The HA- and platelet-rich plasma used
simultaneously rescued the disrupted chondrogenic signaling and enhanced cartilage regeneration [238].
Moreover, the hOAC-laden collagen microspheres, engineered by Yeung et al. [235], responded to OA
disease-modifying factors, such as low oxygen tension and TGF-β.
Besides primary chondrocytes, human stem cells also serve as a promising cell source to engineer
3D cartilage tissues [239,240]. In particular, the higher availability of stem cells like adult MSCs makes
them preferable in engineering individual-specific cartilage tissues for regenerative medicine and
OA studies. It is worth mentioning that the utility of 3D engineered cartilage in OA modeling is
strongly dependent on its physiological relevance of biological accuracy. For example, pellet cultures
typically require a very large number of cells and cell–ECM interaction is absent until newly formed
ECM is generated by cells. On the other hand, in scaffold-based engineered cartilage tissue, cell–cell
interaction cannot be achieved initially, due to the physical separation resulting from encapsulation of
the cells in the biomaterial scaffold. Of special relevance, it is known that intimate cell–cell interaction,
mediated by N-cadherin, a transmembrane protein responsible for homotypic cell–cell adhesion,
is critical in initiating mesenchymal chondrogenesis [241]. To overcome these limitations of the
pellet and scaffold cultures, we have recently established a development-informed protocol to induce
N-cadherin-mediated cellular condensation and subsequent chondrogenesis of human MSCs while
encapsulated within their own ECM, which results in robust cartilage formation [242]. In addition,
given the requisite crosstalk between cartilage and other joint tissues in the native joint, we have
developed an engineered 3D “joint organ” that includes multiple components of the articular joint (see
below), which should offer a physiologically more relevant platform for mechanistic studies on joint
disorders such as OA.
4.2.3. Tissue Explant Models
Although the exact pathogenesis and etiology of OA are not completely understood, the metabolic
state of articular cartilage and its crosstalk with other tissues are believed to play crucial roles in
various proposed mechanisms. Cartilage explants from human patients and animal models have
thus been widely utilized in mechanistic OA studies. Grenier et al. [243] established an in vitro
cartilage degeneration model by treating bovine cartilage explants with collagenase, simulating the
matrix damage typically observed in early-stage OA. We have previously created a traumatized OA
model by impacting a healthy bovine articular cartilage at 36 MPa [45,191]. In a study to explore
the crosstalk between tissue components of the joint organ, particularly subsequent to injurious
insults, we examined the interactions between the IPFP and articular cartilage, before and after
mechanical trauma. The traumatized cartilage was exposed to IPFP-conditioned culture medium,
which was found to aggravate degeneration of the injured cartilage, likely due to elevated IL-6 levels.
The traumatized cartilage-conditioned medium also increased IL-6 expression levels in adipocytes and
adipose stem cells derived from IPFP, indicating IPFP-cartilage crosstalk [244]. Using IPFP-cartilage and
IPFP-meniscus co-cultures, Nishimuta et al. [245] found that co-cultured healthy IPFP could modulate
glycosaminoglycan (GAG) metabolism in cartilage and meniscus and stimulate the production and
accumulation of GAG in cartilage. Furthermore, the authors labeled newly synthesized sulfated
GAGs and proteins with sodium [35S]-sulfate and [3H]-proline, respectively, in cartilage and meniscus
explants and supplemented the culture medium with several adipokines (resistin, leptin, adiponectin,
or visfatin) and found that adipokines induced catabolic changes in newly incorporated matrix in both
tissues [246]. An in vitro cartilage–synovium explant co-culture model has also been established [247].
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The cytokines identified in the co-cultures were found to be more similar to those in OA synovial fluid
than those in monocultures of cartilage or synovium. The synovium-secreted factors reduced GAG
production in the co-cultured OA cartilage. Interestingly, supplementation with the corticosteroid
triamcinolone acetonide (0.1 mM) was found to relieve this inhibitory effect, suggesting the potential
utility of such explant systems in screening for OA [247]. The cartilage–synovium explant co-culture
model has also been used to investigate the efficacy and mechanisms of potential OA therapies. Using
this co-culture model, viscosupplementation (intraarticular injection of HA) was evaluated, and found
to benefit OA joints potentially via an anti-inflammatory mechanism of action and a biosynthetic
chondroprotective mechanism [248].
4.2.4. Microphysiological Systems
A microphysiological system (MPS), sometimes referred to as an organotypic culture model
(OCM), describes an in vitro platform that models human tissues by providing living cells, usually
heterogenous in nature, with a microenvironment supporting specific structure and responses that
define an organ or tissue. The key features of an MPS include the use of human cells, multiple tissue
components, 3D culture, as well as dynamic tissue crosstalk. MPS presents an unprecedented tool for
us to mechanistically understand the functions, interactions, and pathogenesis of tissues/organs, and
promises to serve as a convenient, versatile component that may be adapted for various drug testing
and development scenarios. In view of the “whole joint” nature of OA, an ideal “joint-on-a-chip”
should incorporate all the elements of the joint, and ideally is compatible with the application of
mechanical load and perturbation.
In reality, the development of MPS for OA studies is at an early stage. In most cases, only cartilage
tissue is included. For example, to model excessive mechanical loading-induced OA chondrocyte
phenotypes, Occhetta et al. [249] used human articular chondrocyte-laden hydrogels to develop a
3D human cartilage-on-a-chip (COC) constructed on polydimethylsiloxane (PDMS) (Figure 3A,B).
Under hyperphysiological confined compression (30% confined compression; Figure 3C), the cartilage
microtissues in this microfluidic device displayed increased expression of catabolic enzymes and
inflammatory markers, and chondrocyte hypertrophy [249]. Another PDMS-based COC device was
designed as an in vitro model of equine OA [250]. The cartilage tissue in this model showed enhanced
inflammatory phenotype in response to a 24-h treatment of TNF-α and IL-1β. As noted above, systems
for the preparation and culture of osteochondral tissues have been in development for some time,
and come in many different configurations and materials. Recognizing the importance of replicating
native cartilage–bone crosstalk, we have recently developed microphysiological osteochondral systems
derived from human MSCs or iPSCs (Figure 3D) [251,252]. We observed active cartilage–bone crosstalk
with IL-1β treatment of either bone or cartilage; we also showed the potential of such osteochondral
chips in drug testing and development [252].
Perhaps the biggest advantage of the MPS platform in OA studies is its capability to enable the
interactions and crosstalk among multiple microtissues that correspond to the tissue components
present in specific human joints. Initially considered a disease of cartilage degeneration, OA is now
recognized as a whole-joint disease, involving and affecting not only bone and cartilage. In particular,
synovium and IPFP seem to act as an anatomo-functional unit, which is an emerging idea supported by
recent studies [253,254]. Therefore, a human stem cell-derived MPS model, incorporating osteochondral,
synovial, and adipose tissues within a chip, has been developed by our group and is coined the
“microJoint”, which expands and replicates tissue crosstalk and communication to allow a more
complete and holistic understanding of the process of OA pathogenesis (Figure 4).
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5. Summary and Future Prospects
The significant disease burden of OA and the accompanying compromise to the quality of life of
OA patients notwithstanding, development of effective OA prevention and treatment methods have
been largely unsuccessful. Current treatments are still limited to lifestyle change, physical therapy,
NSAIDs, and end-stage surgical joint replacement. The slow progress in developing novel and effective
therapeutic approaches is primarily attributed to our insufficient understanding of OA etiology and
pathogenesis [255].
Improved understanding of OA causation and pathogenesis is critical in identifying potential
therapeutic targets to prevent disease development and progression. In this review, we have
summarized our current understanding of OA pathogenesis. A concise introduction of OA risk
factors is provided, as they have been widely discussed and are generally accepted. We have focused
on the latest progress in experimental models and regulatory pathways active in OA onset and
development. It is clear that interfering with a single known regulatory pathway will be insufficient in
preventing or inhibiting OA development. Instead, multiple regulatory pathways must be considered,
as well as more upstream targets. A possible strategy is to develop multi-functional molecules
that affect several key pathways or activities. For example, the Wnt inhibitors such as XAV939 and
lorecivivint, not only suppress inflammatory activities, but also promote chondrogenesis [94,256].
In addition, these agents are known to suppress osteogenesis [239,257], and may thus potentially
reduce osteophyte formation.
Valid experimental models of OA are vital to advance research into disease causes and mechanisms,
and function as a platform to screen and test potential therapeutics, thus facilitating rational drug
design and development. Due to the inherent difference among species in physiology, anatomy,
genetics, and metabolism, generating animal models that can faithfully recapitulate all human disease
aspects is inherently challenging, which has hindered basic research and translation to clinical
application. As discussed above, the integration of multiple 3D engineered joint tissue components into
a functionally relevant MPS holds enormous potential as the next generation of OA models. Although
establishing human joint-on-a-chip is still at a relatively early stage, promising data have already
been obtained, supporting the recapitulation of key physiological and pathological features observed
in vivo. As shown in Figure 4, we have recently developed a tissue chip that is capable of mimicking
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tissue–tissue communication through microfluidic flow or diffusion, which has allowed us to assess the
known, important role of joint tissue crosstalk among in OA pathogenesis. Such capability is critical in
enabling the refining tissue target(s) in drug development. However, before the complete validation
of new OA models, traditional approaches, including animal and 2D cell cultures, will continue to
correlate cell and molecular findings with in vivo physiological responses.
There are multiple challenges before MPS becomes an accepted platform for the development of
disease modifying OA drugs (DMOADs). In particular, complex mechanics operates in the articular
joint, which is not only a part of the native functions of the joint, but also plays critical roles in OA
pathogenesis. Although some tissue-on-a-chip models have been developed, how to incorporate the
mechanical mechanism in the context of the MPS is not a simple task. In addition, it has been shown
that both systemic, in particular, OA-associated pain, and local changes participate in OA progression,
and must be incorporated in the MPS. Other requirements include validation of clinical relevance,
standardization issues, and regulatory hurdles, but it is highly encouraging that research interest in the
tissue/organ-on-a-chip area is rapidly rising.
In conclusion, although there are currently no DMOADs with high efficacy, specificity, potency,
and bioavailability [258], with scientific advances in OA pathology and experimental models being
continuously made, we are hopefully not far from achieving our goal of finding a cure for this painful
and debilitating disease.
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